SCHEMBL4164480

SCHEMBL4164480

Cc1cc(C(=O)N2CCCCC2)c(C)s1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.53
MAPK1 P28482 1/20 0.53
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GAA P10253 1/20 0.49
HSP90AA1 P07900 2/20 0.45
ATM Q13315 1/20 0.45
HTT P42858 2/20 0.44
TSHR P16473 2/20 0.44
POLB P06746 1/20 0.44
L3MBTL3 Q96JM7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8235053 0.82 HPGD (0.51) HPGDALDH1A1HTTTSHRL3MBTL3
SCHEMBL13726451 0.79 SPR (0.42) HPGDALDH1A1L3MBTL3L3MBTL1RAB9A
SCHEMBL3841516 0.77 TSHR (0.52) HPGDMAPK1KMT2AALDH1A1MEN1
SCHEMBL12911835 0.77 TSHR (0.52) HPGDMAPK1KMT2AALDH1A1MEN1
SCHEMBL5774818 0.77 TSHR (0.40) HPGDMAPK1KMT2AALDH1A1MEN1
SCHEMBL12195803 0.76 HPGD (0.53) HPGDMAPK1KMT2AALDH1A1MEN1
SCHEMBL4154038 0.72 HPGD (0.49) HPGDMAPK1KMT2AALDH1A1MEN1
SCHEMBL11848005 0.71 ALDH1A1 (0.44) HPGDMAPK1KMT2AALDH1A1MEN1
SCHEMBL2996683 0.71 ALDH1A1 (0.44) MAPK1KMT2AALDH1A1MEN1NPSR1
SCHEMBL4150866 0.70 HPGD (0.50) HPGDMAPK1KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 US disclosed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 US disclosed
CN-1950375-A Glucocorticoid receptor modulator compounds and methods- utility LIGAND PHARM INC (US) 2007-04-18 CN disclosed
EP-1718653-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY Ligand Pharmaceuticals Inc. (US) 2006-11-08 EP disclosed
WO-2005082909-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY LIGAND PHARMACEUTICALS INCORPORATED (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods NR3C1, NR3C2, MC2R HPGD 272/4885MAPK1 1351/4885KMT2A 4088/4885
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods NR3C1, NR3C2, MC2R HPGD 272/4885MAPK1 1351/4885KMT2A 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.